Mentions
Extended reach
Total likes
Video views
AI synopsis
Overall, the discussions express strong agreement, with commenters calling the trial results a 'gamechanger' and noting that Y90 outperforms traditional methods, supported by remarks about the level I evidence from the trial. Their tone and focus on clinical implications demonstrate deep engagement and highlight the potential impact on treatment strategies for unresectable hepatocellular carcinoma.
Most discussions highlight support for the study's positive findings favoring Yttrium-90 radioembolization, reflecting strong agreement with the research conclusions.
The discussions demonstrate high interest by emphasizing the significance of the trial's results and calling it a 'gamechanger,' indicating active engagement with the topic.
Participants reference specific trial outcomes, such as improved overall survival and time to tumor progression, showing deep engagement and analysis of the research findings.
The widespread sharing of the study among prominent radiology and oncology communities suggests a significant influence on current treatment approaches and clinical practice discussions.
TRACE trial out: Y90 outperforms DEBs in BCLC A/B HCC. Sig better TTP + OS. Level I evidence RCT @riadsalemIR @cirsesociety @AASLDtweets @EASLnews @SIRspecialists @ASTRO_org @radiology_rsna @JVIRmedia @bsc_io @SirtexMedical @RSNA https://t.co/kNiVrTpmXl
Yttrium-90 radioembolization vs. chemoembolization for unresectable hepatocellular carcinoma: results from the TRACE phase 2 randomized controlled trial. #InAMinute @RadiologyEditor #RadInTraining @RadITrainEditor @radiology_rsna
@SprakerMDPhD @NiuSanford Not much but there is a small RCT showing OS benefit vs TACE in intermediate stage HCC https://t.co/DBOGXjscKt
@rlevitinMD @nbn426 I think that’s the real question at present. There are data from a prospective phase 2 RCT supporting improved OS with TARE compared with DEB-TACE. Pts were predominately BCLC-B https://t.co/IqNd7mmDxN
@jryckman3 https://t.co/FfywQ96lTy
This video summarizes research comparing yttrium-90 radioembolization to drug-eluting bead chemoembolization for unresectable hepatocellular carcinoma, highlighting improved tumor control and survival outcomes with Y-90…
This episode discusses the latest clinical data on combining transarterial chemoembolization and immunotherapy for hepatocellular carcinoma. The doctors explore emerging treatment trends, multidisciplinary approaches…
@SprakerMDPhD @NiuSanford Not much but there is a small RCT showing OS benefit vs TACE in intermediate stage HCC https://t.co/DBOGXjscKt
RT @JDekervel: @jryckman3 https://t.co/FfywQ96lTy
@jryckman3 https://t.co/FfywQ96lTy
@jryckman3 Yes, here's another trial supporting this: https://t.co/k86tIed3g0
RT @KrishanJethwa: @rlevitinMD @nbn426 I think that’s the real question at present. There are data from a prospective phase 2 RCT support…
@rlevitinMD @nbn426 I think that’s the real question at present. There are data from a prospective phase 2 RCT supporting improved OS with TARE compared with DEB-TACE. Pts were predominately BCLC-B https://t.co/IqNd7mmDxN
RT @MarcDiMartino:
RT @MarcDiMartino:
RT @MarcDiMartino:
@liverwei @navale_pooja @DrGeeONE @ariella8 @vij_mukul @LiverPath_HPHS @liverpath @UKLiverPath Thanks for sending me down the rabbit hole
RT @RyanWEngland: Yttrium-90 radioembolization vs. chemoembolization for unresectable hepatocellular carcinoma: results from the TRACE phas…
<sup>90</sup>Y Proud about this gamechanger!! Radioembolization versus Drug-eluting Bead Chemoembolization for Unresectable Hepatocellular Carcinoma: Results from the TRACE Phase II Randomized Controlled Trial https://t.co/HSUQdkdPki
RT @RyanWEngland: Yttrium-90 radioembolization vs. chemoembolization for unresectable hepatocellular carcinoma: results from the TRACE phas…
RT @NorthwesternIR: TRACE trial out: Y90 outperforms DEBs in BCLC A/B HCC. Sig better TTP + OS. Level I evidence RCT @riadsalemIR @cirsesoc…
90Y Radioembolization versus Drug-eluting Bead Chemoembolization for Unresectable Hepatocellular Carcinoma: Results from the TRACE Phase II Randomized Controlled Trial | Radiology https://t.co/SFy7ZhMGkG https://t.co/XF0BW2Dr4h
RT @NorthwesternIR: TRACE trial out: Y90 outperforms DEBs in BCLC A/B HCC. Sig better TTP + OS. Level I evidence RCT @riadsalemIR @cirsesoc…
RT @RyanWEngland: Yttrium-90 radioembolization vs. chemoembolization for unresectable hepatocellular carcinoma: results from the TRACE phas…
RT @RyanWEngland: Yttrium-90 radioembolization vs. chemoembolization for unresectable hepatocellular carcinoma: results from the TRACE phas…
RT @RyanWEngland: Yttrium-90 radioembolization vs. chemoembolization for unresectable hepatocellular carcinoma: results from the TRACE phas…
RT @NorthwesternIR: TRACE trial out: Y90 outperforms DEBs in BCLC A/B HCC. Sig better TTP + OS. Level I evidence RCT @riadsalemIR @cirsesoc…
RT @RyanWEngland: Yttrium-90 radioembolization vs. chemoembolization for unresectable hepatocellular carcinoma: results from the TRACE phas…
RT @NorthwesternIR: TRACE trial out: Y90 outperforms DEBs in BCLC A/B HCC. Sig better TTP + OS. Level I evidence RCT @riadsalemIR @cirsesoc…
RT @RyanWEngland: Yttrium-90 radioembolization vs. chemoembolization for unresectable hepatocellular carcinoma: results from the TRACE phas…
RT @RyanWEngland: Yttrium-90 radioembolization vs. chemoembolization for unresectable hepatocellular carcinoma: results from the TRACE phas…
RT @NorthwesternIR: TRACE trial out: Y90 outperforms DEBs in BCLC A/B HCC. Sig better TTP + OS. Level I evidence RCT @riadsalemIR @cirsesoc…
RT @NorthwesternIR: TRACE trial out: Y90 outperforms DEBs in BCLC A/B HCC. Sig better TTP + OS. Level I evidence RCT @riadsalemIR @cirsesoc…
RT @NorthwesternIR: TRACE trial out: Y90 outperforms DEBs in BCLC A/B HCC. Sig better TTP + OS. Level I evidence RCT @riadsalemIR @cirsesoc…
RT @NorthwesternIR: TRACE trial out: Y90 outperforms DEBs in BCLC A/B HCC. Sig better TTP + OS. Level I evidence RCT @riadsalemIR @cirsesoc…
RT @RyanWEngland: Yttrium-90 radioembolization vs. chemoembolization for unresectable hepatocellular carcinoma: results from the TRACE phas…
RT @NorthwesternIR: TRACE trial out: Y90 outperforms DEBs in BCLC A/B HCC. Sig better TTP + OS. Level I evidence RCT @riadsalemIR @cirsesoc…
RT @NorthwesternIR: TRACE trial out: Y90 outperforms DEBs in BCLC A/B HCC. Sig better TTP + OS. Level I evidence RCT @riadsalemIR @cirsesoc…
RT @NorthwesternIR: TRACE trial out: Y90 outperforms DEBs in BCLC A/B HCC. Sig better TTP + OS. Level I evidence RCT @riadsalemIR @cirsesoc…
RT @RyanWEngland: Yttrium-90 radioembolization vs. chemoembolization for unresectable hepatocellular carcinoma: results from the TRACE phas…
RT @NorthwesternIR: TRACE trial out: Y90 outperforms DEBs in BCLC A/B HCC. Sig better TTP + OS. Level I evidence RCT @riadsalemIR @cirsesoc…
RT @RyanWEngland: Yttrium-90 radioembolization vs. chemoembolization for unresectable hepatocellular carcinoma: results from the TRACE phas…
RT @RyanWEngland: Yttrium-90 radioembolization vs. chemoembolization for unresectable hepatocellular carcinoma: results from the TRACE phas…
RT @NorthwesternIR: TRACE trial out: Y90 outperforms DEBs in BCLC A/B HCC. Sig better TTP + OS. Level I evidence RCT @riadsalemIR @cirsesoc…
RT @NorthwesternIR: TRACE trial out: Y90 outperforms DEBs in BCLC A/B HCC. Sig better TTP + OS. Level I evidence RCT @riadsalemIR @cirsesoc…
RT @NorthwesternIR: TRACE trial out: Y90 outperforms DEBs in BCLC A/B HCC. Sig better TTP + OS. Level I evidence RCT @riadsalemIR @cirsesoc…
RT @NorthwesternIR: TRACE trial out: Y90 outperforms DEBs in BCLC A/B HCC. Sig better TTP + OS. Level I evidence RCT @riadsalemIR @cirsesoc…
RT @RyanWEngland: Yttrium-90 radioembolization vs. chemoembolization for unresectable hepatocellular carcinoma: results from the TRACE phas…
RT @NorthwesternIR: TRACE trial out: Y90 outperforms DEBs in BCLC A/B HCC. Sig better TTP + OS. Level I evidence RCT @riadsalemIR @cirsesoc…
RT @RyanWEngland: Yttrium-90 radioembolization vs. chemoembolization for unresectable hepatocellular carcinoma: results from the TRACE phas…
RT @NorthwesternIR: TRACE trial out: Y90 outperforms DEBs in BCLC A/B HCC. Sig better TTP + OS. Level I evidence RCT @riadsalemIR @cirsesoc…
RT @NorthwesternIR: TRACE trial out: Y90 outperforms DEBs in BCLC A/B HCC. Sig better TTP + OS. Level I evidence RCT @riadsalemIR @cirsesoc…
RT @RyanWEngland: Yttrium-90 radioembolization vs. chemoembolization for unresectable hepatocellular carcinoma: results from the TRACE phas…
RT @NorthwesternIR: TRACE trial out: Y90 outperforms DEBs in BCLC A/B HCC. Sig better TTP + OS. Level I evidence RCT @riadsalemIR @cirsesoc…
TRACE trial out: Y90 outperforms DEBs in BCLC A/B HCC. Sig better TTP + OS. Level I evidence RCT @riadsalemIR @cirsesociety @AASLDtweets @EASLnews @SIRspecialists @ASTRO_org @radiology_rsna @JVIRmedia @bsc_io @SirtexMedical @RSNA https://t.co/kNiVrTpmXl
RT @RyanWEngland: Yttrium-90 radioembolization vs. chemoembolization for unresectable hepatocellular carcinoma: results from the TRACE phas…
RT @RyanWEngland: Yttrium-90 radioembolization vs. chemoembolization for unresectable hepatocellular carcinoma: results from the TRACE phas…
RT @RyanWEngland: Yttrium-90 radioembolization vs. chemoembolization for unresectable hepatocellular carcinoma: results from the TRACE phas…
RT @RyanWEngland: Yttrium-90 radioembolization vs. chemoembolization for unresectable hepatocellular carcinoma: results from the TRACE phas…
Yttrium-90 radioembolization vs. chemoembolization for unresectable hepatocellular carcinoma: results from the TRACE phase 2 randomized controlled trial. #InAMinute @RadiologyEditor #RadInTraining @RadITrainEditor @radiology_rsna
New article: 90Y Radioembolization versus Drug-eluting Bead Chemoembolization for Unresectable Hepatocellular Carcinoma: Results from the TRACE Phase II Randomized Controlled Trial https://t.co/I2b10sS9cS #livercancer #oncology https://t.co/7lR2v0UY8q
doi:10.1148/radiol.211806. [91] Vouche M, Lewandowski RJ, Atassi R, Memon K, Gates VL, Ryu RK, et al. Radiation lobectomy: Time-dependent analysis of future ...
doi:10.1148/radiol.211806 14. Ricke J, Bulla K, Kolligs F, et al; SORAMIC study group. Safety and toxicity of radioembolization plus ...
doi:10.1148/radiol.211806. 4. Ricke J, Bulla K, Kolligs F, et al; SORAMIC study group. Safety and toxicity of radioembolization plus ...
N
RM
MM
JD
KJ
JR
RW
AP
MH
NR
AR
BT
A
HV
EB
JS
SP
MT
MD
TW
MM
BR
HY
JH
VF
NK
DS
JF
C
A
TR
KE
KD
Hا
RS
DE
MM
DM
CM
UV
A
SF
PK
AB
HS
MD
LT
CM
AM
FM
PO